AU2008279619B2 - Antibodies to CD200 and uses thereof in inhibiting immune responses - Google Patents

Antibodies to CD200 and uses thereof in inhibiting immune responses Download PDF

Info

Publication number
AU2008279619B2
AU2008279619B2 AU2008279619A AU2008279619A AU2008279619B2 AU 2008279619 B2 AU2008279619 B2 AU 2008279619B2 AU 2008279619 A AU2008279619 A AU 2008279619A AU 2008279619 A AU2008279619 A AU 2008279619A AU 2008279619 B2 AU2008279619 B2 AU 2008279619B2
Authority
AU
Australia
Prior art keywords
antibody
cells
agent
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008279619A
Other languages
English (en)
Other versions
AU2008279619A1 (en
Inventor
Susan Faas Mcknight
Russell P. Rother
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2008279619A1 publication Critical patent/AU2008279619A1/en
Application granted granted Critical
Publication of AU2008279619B2 publication Critical patent/AU2008279619B2/en
Priority to AU2014200678A priority Critical patent/AU2014200678A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2008279619A 2007-07-25 2008-07-25 Antibodies to CD200 and uses thereof in inhibiting immune responses Ceased AU2008279619B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014200678A AU2014200678A1 (en) 2007-07-25 2014-02-07 Antibodies to CD200 and uses thereof in inhibiting immune responses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
US60/962,022 2007-07-25
PCT/US2008/009037 WO2009014745A1 (en) 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014200678A Division AU2014200678A1 (en) 2007-07-25 2014-02-07 Antibodies to CD200 and uses thereof in inhibiting immune responses

Publications (2)

Publication Number Publication Date
AU2008279619A1 AU2008279619A1 (en) 2009-01-29
AU2008279619B2 true AU2008279619B2 (en) 2013-11-14

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008279619A Ceased AU2008279619B2 (en) 2007-07-25 2008-07-25 Antibodies to CD200 and uses thereof in inhibiting immune responses

Country Status (9)

Country Link
US (3) US8252285B2 (enExample)
EP (1) EP2178561A1 (enExample)
JP (4) JP2010534243A (enExample)
KR (1) KR20100041849A (enExample)
AU (1) AU2008279619B2 (enExample)
BR (1) BRPI0814644A2 (enExample)
CA (1) CA2697159C (enExample)
MX (1) MX2010000981A (enExample)
WO (1) WO2009014745A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534243A (ja) * 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用
MX2012009321A (es) * 2010-02-11 2012-11-21 Alexion Pharma Inc Metodos terapeuticos que utilizan anticuerpos anti-cd200.
JP6150734B2 (ja) * 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
EP3150632B1 (en) 2011-06-10 2020-04-08 Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence Anti-ricin antibodies and uses thereof
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
US9737598B2 (en) * 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
EP3911357A1 (en) 2019-01-14 2021-11-24 Regents of the University of Minnesota Cd200ar ligands for cancer immunotherapy
EP4296280A1 (en) * 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2004060295A2 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
CA2694121C (en) 2007-07-25 2016-06-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
JP2010534243A (ja) 2007-07-25 2010-11-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２００に対する抗体および免疫応答への使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084321A2 (en) * 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof

Also Published As

Publication number Publication date
US20100291085A1 (en) 2010-11-18
USRE46323E1 (en) 2017-02-28
US8637014B2 (en) 2014-01-28
WO2009014745A1 (en) 2009-01-29
US8252285B2 (en) 2012-08-28
CA2697159A1 (en) 2009-01-29
JP5926702B2 (ja) 2016-05-25
JP2010534243A (ja) 2010-11-04
JP2016117762A (ja) 2016-06-30
BRPI0814644A2 (pt) 2015-01-27
KR20100041849A (ko) 2010-04-22
CA2697159C (en) 2017-02-14
EP2178561A1 (en) 2010-04-28
AU2008279619A1 (en) 2009-01-29
US20120321625A1 (en) 2012-12-20
JP2013163695A (ja) 2013-08-22
JP2015172090A (ja) 2015-10-01
MX2010000981A (es) 2010-05-21

Similar Documents

Publication Publication Date Title
AU2008279619B2 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses
US8709415B2 (en) Antibodies to OX-2/CD200 and uses thereof
US20070148162A1 (en) Molecule which binds cd80 and cd86
US20120269806A1 (en) Methods of inducing tolerance
JP2023016923A (ja) 調節性ｔ細胞及びその使用
US8986684B2 (en) Methods and compositions for treating autoimmune disease
KR102710759B1 (ko) 이식편대숙주 질환을 예방하는 방법
JP2025066696A (ja) 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
AU2014200678A1 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
EA050337B1 (ru) Применение мат против ccr7 для предотвращения или лечения реакции "трансплантат против хозяина" (ртпх)
HK1172343A (en) Antibodies to ox-2/cd200 and uses thereof
HK1091844A1 (en) Therapeutic humanised antibodies against cd45 isoforms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired